高剂量率近距离治疗单药与剂量递增外照射治疗局限期前列腺癌的直肠毒性比较
基于前瞻性机构数据库,比较2683例局限期前列腺癌患者接受高剂量率(HDR)近距离治疗单药与外照射放疗(EBRT)后的直肠毒性。HDR组急性≥2级腹泻、直肠疼痛/里急后重和直肠出血发生率均显著低于EBRT组,慢性≥2级直肠出血和放射性直肠炎发生率也显著更低。结论认为HDR近距离治疗单药是减少直肠毒性的有效策略。
要点
- HDR组急性≥2级腹泻、直肠疼痛/里急后重和直肠出血发生率均显著低于EBRT组。
- HDR组慢性≥2级直肠出血和放射性直肠炎发生率显著低于EBRT组。
- HDR组任何慢性≥2级直肠毒性发生率为2.4%,显著低于EBRT组的10.5%。
核心结论
- 在适当选择的局限期前列腺癌患者中,HDR近距离治疗单药是减少直肠毒性的有效策略。
研究设计与样本
- 基于前瞻性收集的机构数据库,纳入1994年至2017年间接受HDR或EBRT治疗的2683例局限期前列腺癌患者。
- HDR分次方案为38 Gy/4次(n=321)、24 Gy/2次(n=96)或27 Gy/2次(n=128)。
- EBRT患者接受中位剂量75.6 Gy,分次剂量1.8 Gy(范围70.2-82.8 Gy),采用3D适形或调强放疗(IMRT),并通过离线自适应流程进行3D图像引导。
主要发现
- 中位随访7.5年(EBRT组7.4年,HDR组7.9年);545例(20.3%)接受HDR,2138例(79.7%)接受EBRT;69.1%的EBRT患者接受IMRT。
- HDR组与EBRT组比较:急性≥2级腹泻发生率0.7% vs. 4.5%(p < 0.001),直肠疼痛/里急后重0.6% vs. 7.9%(p < 0.001),直肠出血0% vs. 1.6%(p = 0.001)。
- HDR组与EBRT组比较:慢性≥2级直肠出血发生率1.3% vs. 8.7%(p < 0.001),放射性直肠炎0.9% vs. 3.3%(p = 0.001)。
- HDR组与EBRT组任何慢性≥2级直肠毒性发生率分别为2.4% vs. 10.5%(p < 0.001)。
- 在接受IMRT的患者中,急性和慢性任何≥2级胃肠道毒性发生率显著降低,但仍显著高于接受HDR治疗的患者。
临床怎么用
- 对于适当选择的局限期前列腺癌患者,可考虑HDR近距离治疗单药以降低直肠毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Using a prospectively collected institutional database, we compared rectal toxicity following high dose rate (HDR) brachytherapy as monotherapy relative to dose-escalated external beam radiotherapy (EBRT) for patients with localized prostate cancer. METHODS: 2683 patients treated with HDR or EBRT between 1994 and 2017 were included. HDR fractionation was 38 Gy/4 fractions (n = 321), 24 Gy/2 (n = 96), or 27 Gy/2 (n = 128). EBRT patients received a median dose of 75.6 Gy in 1.8 Gy fractions [range 70.2-82.8 Gy], using either 3D conformal or intensity modulated radiotherapy (IMRT). EBRT patients underwent 3D image guidance via an off-line adaptive process. RESULTS: Median follow-up was 7.5 years (7.4 years for EBRT and 7.9 years for HDR). 545 patients (20.3%) received HDR brachytherapy and 2138 (79.7%) EBRT. 69.1% of EBRT patients received IMRT. Compared to EBRT, HDR was associated with decreased rates of acute grade ≥2 diarrhea (0.7% vs. 4.5%, p < 0.001), rectal pain/tenesmus (0.6% vs. 7.9%, p < 0.001), and rectal bleeding (0% vs. 1.6%, p = 0.001). Rates of chronic grade ≥2 rectal bleeding (1.3% vs. 8.7%, p < 0.001) and radiation proctitis (0.9% vs. 3.3%, p = 0.001) favored HDR over EBRT. Rates of any chronic rectal toxicity grade ≥2 were 2.4% vs. 10.5% (p < 0.001) for HDR versus EBRT, respectively. In those treated with IMRT, acute and chronic rates of any grade ≥2 GI toxicity were significantly reduced but remained significantly greater than those treated with HDR. CONCLUSIONS: In appropriately selected patients with localized prostate cancer undergoing radiation therapy, HDR brachytherapy as monotherapy is an effective strategy for reducing rectal toxicity.
引用
- Parzen JS, Ye H, Gustafson G, et al. Rates of rectal toxicity in patients treated with high dose rate brachytherapy as monotherapy compared to dose-escalated external beam radiation therapy for localized prostate cancer. Radiother Oncol. 2020. PMID: 32276193. doi:10.1016/j.radonc.2020.03.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。